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Abstract: The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target 
of therapy in the primary and secondary prevention of cardiovascular events. Although statin 
therapy is the mainstay for LDL-C lowering, a significant percentage of patients prescribed these 
agents either do not achieve targets with statin therapy alone or have partial or complete intoler-
ance to them. For such patients, the use of adjuvant therapy capable of providing incremental 
LDL-C reduction is advised. One such agent is ezetimibe, a cholesterol absorption inhibitor that 
targets uptake at the jejunal enterocyte brush border. Its primary target of action is the cholesterol 
transport protein Nieman Pick C1 like 1 protein. Ezetimibe is an effective LDL-C lowering agent 
and is safe and well tolerated. In response to significant controversy surrounding the use and 
therapeutic effectiveness of this drug, we provide an update on the biochemical mechanism of 
action for ezetimibe, its safety and efficacy, as well as the results of recent randomized studies 
that support its use in a variety of clinical scenarios.
Keywords: bile, coronary artery disease, ezetimibe, low-density lipoprotein cholesterol, Nieman 
pick C1 like 1 protein, statin
Introduction
The association between elevated serum cholesterol levels and risk of cardiovascular 
disease has been well established through a number of epidemiologic studies, such as 
the Framingham Heart Study and the Seven Countries Study.1,2 Multiple randomized 
controlled trials over the past two decades have consistently shown that treatment with 
3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in 
dyslipidemic patients with and without established vascular disease effectively lowers 
low-density lipoprotein cholesterol (LDL-C) levels and reduces major cardiovascular 
events.3–7 Based upon these lines of evidence, the National Cholesterol Education 
Program (NCEP) through the Adult Treatment Panel (ATP) III has recommended 
reducing LDL-C levels as the primary goal and supports the use of statins as the initial 
preferred therapy.8 Recent trials have suggested that more aggressive lowering of 
LDL-C to levels of ,70 mg/dL may result in incremental cardiovascular benefit.9–11 
Therefore, ATP III was updated to include an optional LDL-C goal of ,70 mg/dL 
in very high-risk patients that have established cardiovascular disease with multiple 
cardiac risk factors.12
Despite growing evidence supporting a lower-is-better approach for LDL-C, 
treatment with statin therapy alone may not be sufficient to achieve optimal LDL-C 
targets, with some patients requiring greater than a 50% reduction.13 Institutional surveys 
have shown that only two-thirds of vascular disease patients are at an LDL-C goal of 
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,100 mg/dL and less than a third of very high-risk patients 
are able to reach an LDL-C goal of ,70 mg/dL.14,15 Based 
upon these treatment failures, combination therapies using 
multiple cholesterol-lowering agents including ezetimibe in 
addition to statin therapy have been investigated.16,17 While 
ATP III recommends statin therapy as the first-line agent 
for the treatment of elevated LDL-C, alternative therapies 
such as ezetimibe, niacin, bile-acid sequestrants, and ileal 
bypass surgery can also effectively lower LDL-C.17–20 A 
recent meta-analysis has shown that these nonstatin-based 
treatments can lower cardiac events similar to statin therapies, 
with an equivalent observed relationship between degree of 
LDL-C lowering and reduction in coronary heart disease 
(CHD) risk.21 These data suggest that the addition of these 
therapies to a background of statin treatment may produce 
an incremental lowering of LDL-C, and possibly result in a 
further reduction in cardiovascular events.
Ezetimibe inhibits intestinal and biliary cholesterol 
absorption and can significantly lower LDL-C and nonhigh-
density lipoprotein cholesterol (non-HDL-C, defined as 
total cholesterol minus high-density lipoprotein cholesterol) 
when used alone or in combination with statin therapy.22 
Despite the established cholesterol-lowering benefits of 
ezetimibe, significant controversy exists with respect to 
ezetimibe’s vascular and clinical benefit, particularly in light 
of the Ezetimibe and Simvastatin in Hypercholesterolemic 
Enhances Atherosclerosis Regression (ENHANCE) trial, 
which showed no difference in carotid atherosclerosis burden 
as measured by carotid intima-media thickness (CIMT) in 
patients with heterozygous familial hypercholesterolemia 
who were treated with simvastatin plus either ezetimibe or 
placebo.17,23 Based upon this controversy, some providers 
eliminated or reserved the use of ezetimibe as a last-line agent 
in lipid management. This review aims to detail the biological 
mechanisms, lipid effects, and safety of ezetimibe treatment 
and discuss the vascular and clinical outcomes data that may 
impact the use of ezetimibe in clinical practice.
Mechanism of action
Circulating plasma levels of cholesterol are derived from 
two primary sources: cholesterol production from the liver 
and peripheral tissues, and the absorption of dietary and 
biliary cholesterol in the gastrointestinal tract (Figure 1).24,25 
Cholesterol synthesis begins with the conversion of 
acetyl-CoA to mevalonate, a reaction catalyzed by the 
enzyme HMG-CoA reductase.26 Cholesterol synthesized 
by hepatocytes undergoes esterification by acyl-CoA acyl 
transferase (ACAT) and is incorporated into apolipoprotein 
B (ApoB)-containing lipoproteins such as very-low-density 
lipoprotein (VLDL) via microsomal transfer protein.27,28 
Subsequent modification of VLDL with hydrolysis of 
triglycerides by the enzymes lipoprotein lipase and hepatic 
lipase produces intermediate-density lipoprotein (IDL) and 
LDL. The transfer of cholesterol from the peripheral tissues 
to the liver is mediated by HDL.29 Nascent pre-β HDL 
particles accept free cholesterol from peripheral tissues 
via ATP-binding cassette transporter A1 (ABCA1). The 
cholesterol undergoes subsequent esterification by lecithin–
cholesterol acetyltransferase. The esterified cholesterol 
moves into the hydrophobic core of the HDL particle, and 
as the particles become progressively more lipidated, they 
mature and become progressively larger and more spherical. 
The cholesteryl esters in these mature HDL particles can be 
removed from the circulation by hepatic scavenger receptor 
BI or undergo transfer of cholesterol to apolipoprotein 
B-containing lipoproteins such as LDL and IDL via the 
activity of cholesteryl ester transfer protein.30 The liver clears 
LDL particles from the circulation by the LDL receptor and 
the LDL receptor-related protein.27,28
Intestinal cholesterol absorption, occurring primarily in 
the duodenum and proximal jejunum, can also contribute 
to serum cholesterol levels.31,32 Dietary intake provides 
about a quarter of the cholesterol entering the intestinal 
lumen, while the remaining three-quarters are derived from 
biliary cholesterol excretion from the liver. A distinction 
must be drawn between cholesterol entry into enterocytes 
and systemic cholesterol absorption, which refers to the 
appearance of cholesterol within lymphatic vessels, as not all 
of the cholesterol that makes its way into enterocytes will be 
absorbed into plasma. Intestinal cholesterol absorption is a 
complex process involving incorporation of free cholesterol, 
the majority of which is of biliary origin, into mixed biliary 
micelles, and the subsequent delipidation of micelles via 
intestinal enterocyte membrane sterol influx transporters.33 
Once in the enterocyte, free cholesterol can be effluxed to 
ApoA-1, prebeta HDL, or ApoE, esterified by ACAT into 
cholesteryl ester for incorporation into ApoB48-containing 
chylomicrons, or effluxed back to the gut lumen by ABC 
transporters G5 and G8. Genetic mutations in ABCG5 and 
ABCG8 proteins result in sitosterolemia, which is associated 
with an increase in phytosterol accumulation and intestinal 
cholesterol absorption resulting in significantly elevated 
plasma cholesterol and plant sterol levels and clinical 
development of early atherosclerotic heart disease.34–36 
After secretion into the lymphatic system and drainage 
via the thoracic duct, chylomicrons and their remnants are 
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cleared from the circulation by the liver. The triglycerides 
and cholesterol esters derived from chylomicrons can be 
repackaged into VLDL and secreted.
In 2004, Altmann et al reported the discovery of the 
Niemann–Pick C1-like 1 protein (NPC1L1) as the human 
sterol transport protein that was expressed at the enterocyte/
gut lumen (apical) as well as the hepatobiliary (canalicular) 
interface.37 NPC1L1 has a sterol-sensing domain, which is 
a region consisting of around 180 amino acids that form 
five predicted membrane-spanning helices with short 
intervening loops.38,39 Current evidence points to the NPC1L1 
protein working in conjunction with the adaptor protein 2 
(AP2) complex and clathrin to facilitate internalization of 
free cholesterol into the enterocyte (Figure 2). AP2 is a 
classical AP that facilitates the internalization of molecules 
into cells, such as cholesterol entering clathrin-coated 
pits. The AP2 complex consists of four proteins forming a 
core and appendage domains. The core carries cholesterol, 
and the appendage or “ears” bind to clathrin, which has a 
triskelion shape (three interlocked spirals) composed of 
three heavy chains and three light chains, which align to 
form small vesicles capable of internalizing cholesterol.40 
Cholesterol in the gut lumen or bile incorporates into the cell 
membrane, where it can bind to the sterol-sensing domain of 
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Figure 1 Lipid and lipoprotein metabolism. 
Notes: Cholesterol, phytosterols and other lipids enter biliary micelles and are internalized via the NPC1L1 protein and the AP2/clathrin complex. Cholesterol can also 
reenter hepatocytes from the bile via canalicular NPC1L1. Nearly all phytosterols and some cholesterol are returned to the gut lumen or to the bile from hepatocytes 
via ABCG5 and ABCG8. Cholesterol can be converted in hepatocytes to primary bile acids, which are effluxed to the bile via ABCB11. ApoA-I is secreted by the liver 
or enterocyte or enters plasma on a chylomicron. VLDLs and chylomicrons traffic TG to muscle and adipocyte tissues. During lipolysis, surface phospholipids as well as 
fatty acids from the TG are also released: the resultant chylomicron remnant is cleared by the liver and the VLDL is converted to IDL, most of which are cleared by LDL 
receptors in the liver but some undergo additional lipolysis and form LDLs. During their plasma residence time the ApoB particles utilizing CETP exchange TG for CE with 
HDL particles. Smaller HDLs are lipidated at ABCA1, and larger HDLs at ABCG1 or SR B1. Larger HDLs can be delipidated by SR B1 at the liver, on adipocytes, or in 
steroidogenic tissues.
Abbreviations: ABCA1, ATP-binding cassette transporter A1 (cholesterol efflux); ABCG1, ATP-binding cassette transporter (cholesterol efflux); ABCG5, ABCG8, ATP-
binding cassette transporters G5 and G8 (sterol efflux); ABCB11, ATP-binding cassette transporter B11 (bile export pump); AP2, adaptor protein 2; ApA, apolipoprotein A; 
CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; HDL2, larger HDL species; HDL3, smaller HDL species; IDL, intermediate-density lipoprotein; LPL, lipoprotein 
lipase; NPC1L1, Niemann–Pick C1-like 1 protein; SR B1, scavenger receptor B1; TG, triglyceride; TICE, transintestinal cholesterol efflux (putative receptor); VLDL, very 
low-density lipoprotein.
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Figure 2 Effect of ezetimibe on NPC1L1-mediated internalization of cholesterol. 
Notes: NPC1L1 protein recycles between the plasma cell membrane and endocytic recycling compartment. When the extracellular cholesterol concentration is high, 
cholesterol is incorporated into the cell membrane and is sensed by cell surface–localized NPC1L1. NPC1L1 and cholesterol are then internalized together through clathrin/
AP2-mediated endocytosis and transported along microfilaments to the ERC in vesicles. The ERC is where cholesterol and NPC1L1 are stored. When the intracellular 
cholesterol level is low, ERC-localized NPC1L1 moves back to the PM along microfilaments in order to absorb cholesterol. Ezetimibe hinders the interaction of the NPC1L1/
cholesterol complex with the AP2-clathrin complex. 
Copyright © 2008, Elsevier. Adapted with permission from Ge L, Wang J, Qi W, et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced 
internalization of NPC1L1. Cell Metab. 2008;7:508–519.41
Abbreviations: AP2, adaptor protein 2; ERC, endocytic recycling compartment; NPC1L1, Niemann–Pick C1-like 1 protein; PM, plasma membrane.
NPC1L1. The NPC1L1/cholesterol complex is internalized 
or endocytosed by joining to AP2 clathrin, creating a vesicle 
complex that then translocates with the help of myosin along 
microfilaments in the cytosol to a storage endosome called 
the endocytic recycling compartment. When intracellular 
cholesterol becomes low the NPC1L1 is released from the 
endocytic recycling compartment and traffics back along 
microfilaments to the cell membrane.41
Serum cholesterol levels are regulated based upon an 
interactive relationship between hepatic cholesterol production 
and intestinal cholesterol absorption.42 Statin therapy reduces 
serum LDL-C by inhibiting hepatic cholesterol production 
through inhibition of the rate-limiting step in cholesterol 
synthesis catalyzed by HMG-CoA reductase.26 In response 
to the decrease in hepatic cholesterol production, the liver 
upregulates hepatic LDL receptors, leading to an increase 
in LDL-C removal from the blood. Additionally, studies 
have shown that in response to statin treatment, there is a 
compensatory increase in intestinal cholesterol absorption, 
possibly through the induction of gene expression of such 
proteins such as NPC1L1.26,43 As a corollary, increases in 
intestinal absorption can lead to downregulation of intrinsic 
hepatic cholesterol production.42,44
Ezetimibe, or 1-(4-fluorophenyl)-(3R)-[3-{4-fluorophenyl}-
{3S}-hydroxyprophyl]-(4S)-(4-hydroxyphenyl)-(2-azetidi-
none), inhibits intestinal cholesterol absorption by selectively 
blocking the NPC1L1 protein in the jejunal brush border, 
integral to the uptake of intestinal lumen micelles into the 
enterocyte.24,37,45,46 The exact mechanism by which ezetimibe 
reduces the entry of cholesterol into both enterocytes and 
hepatocytes is not completely understood. Ge et al suggest 
ezetimibe prevents the NPC1L1/sterol complex from interact-
ing with AP2 in clathrin coated vesicles. Ezetimibe may change 
the shape of NPC1L1 so as to render it incapable of binding 
to sterols or may interfere with the binding of free cholesterol 
to the cell membrane.41 Other hypotheses have been proposed. 
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Kramer et al described a 145-kDa integral membrane-bound 
ectoenzyme called aminopeptidase N ([alanyl]-aminopeptidase) 
to which ezetimibe binds.47 Annexins are a family of calcium- 
and phospholipid-binding proteins that mediate cholesterol 
uptake. Caveolin-1 (CAV1) is a small 22-kDa protein that forms 
at least two distinct chaperone complexes that regulate both total 
cellular and caveolar cholesterol levels. A complex consisting of 
annexin 2, cyclophilin A, and cyclophilin 40, traffics exogenous 
cholesterol from caveolae to the endoplasmic reticulum. The 
other CAV1 complex includes heat-shock protein 56, cyclo-
philin A, and cyclophilin 40, and traffics newly synthesized 
cholesterol from the endoplasmic reticulum to caveolae. It 
has been shown that ezetimibe effectively disrupts the CAV1–
annexin 2 heterocomplex in vivo and thereby reduces sterol 
absorption.48 By reducing enterocyte cholesterol absorption, 
chylomicron formation and secretion, as well as the back flux 
of cholesterol from the bile, ezetimibe depletes hepatic pools of 
cholesterol and increases expression of the LDL receptor on the 
surface of hepatocytes, resulting in reductions in serum levels 
of LDL-C.49 Ezetimibe does not appear to affect the absorption 
of dietary triglycerides, fat-soluble vitamins, or drugs such as 
warfarin. After being metabolized through glucoronidation in 
the small intestine and liver, ezetimibe is excreted in the bile 
back into the intestinal lumen, where it again can inhibit the 
NPC1L1 protein.50,51 It is eventually excreted predominantly 
in the feces, with a minor 10% excretion in the urine. This 
enterohepatic circuit allows ezetimibe to have a long half-
life of 22 hours. Ezetimibe does not undergo metabolism via 
the cytochrome P450 pathway, and therefore does not have 
significant interactions with other medications that are metabo-
lized by the cytochrome P450 pathway, such as statins, fibrates, 
amiodarone, and amlodipine.52 Medications such as fibrates 
and cyclosporine, though, have been shown to increase the bio-
availability of ezetimibe. In addition to inhibition of intestinal 
cholesterol absorption, ezetimibe also interacts with hepatic 
NPC1L1, whereby it may reduce biliary cholesterol absorption 
and further reduce serum cholesterol levels.53
A number of preclinical animal studies have shown a 
consistent reduction in LDL-C levels and vascular benefit 
with treatment with ezetimibe.54–57 Studies using animals 
fed cholesterol-rich diets showed that ezetimibe effectively 
lowered serum cholesterol levels.54 In ApoE double-knockout 
mice characterized by severely elevated cholesterol levels 
and early development of atherosclerosis, ezetimibe at a 
dosing of 10 mg/kg per day inhibited cholesterol intestinal 
absorption by greater than 90%, with significantly reduced 
levels of chylomicron and VLDL by 87%.55 A synergistic 
effect of cholesterol lowering was found in dogs treated with 
a combination of ezetimibe and statin.57 In addition to the 
antilipidemic effects, ezetimibe has been shown to inhibit 
the progression of aortic and carotid atherosclerosis in ApoE 
knockout mice treated with varying diets.56
Ezetimibe appears to have reported marked variability 
in intestinal cholesterol absorption and serum cholesterol 
levels.58 Genomic studies have identified over 140 poly-
morphisms in the NPC1L1 gene and shown that common 
variants in this gene are associated with differing treatment 
responses.59,60 For example, one identified gene variant, 
single-nucleotide polymorphism g. – 18C . A, was associ-
ated with a 15% further reduction in LDL-C as compared to 
the most common allele after 6 weeks of ezetimibe added 
on to a background of statin treatment.59
Statin therapy significant lowers LDL-C cholesterol levels 
by 35%–60%.4,26 While inhibition of hepatic cholesterol 
production by statins results in a compensatory increase 
in the production of hepatic LDL receptors and enhanced 
uptake of serum LDL-C into the liver, there is also an 
increase in intestinal cholesterol absorption.26 Likewise, in 
animal models, treatment with ezetimibe as monotherapy 
has been shown to induce HMG-CoA reductase expression.24 
Given these compensatory effects, the adjunctive treatment 
of hypercholesterolemia using inhibitors of cholesterol 
absorption such as ezetimibe with statins yields an additive 
effect on lowering serum cholesterol levels.61
Efficacy and indications
Ezetimibe is indicated in the treatment of disorders of 
elevated cholesterol levels, including LDL-C and ApoB, 
as monotherapy or in combination with statins.22 The 
effectiveness of ezetimibe to lower cholesterol and positively 
change lipid profiles has been noted in a number of clinical 
trials.17,62–64 Given the preponderance of data demonstrating 
the clinical effectiveness of statin therapy and the current 
NCEP ATP recommendations for the primary use of statin 
medications to achieve LDL-C targets, there have only 
been a small number of clinical trials testing ezetimibe 
as monotherapy versus placebo. A meta-analysis of eight 
randomized placebo controlled trials that included over 
2700 subjects showed that monotherapy with ezetimibe 
10 mg daily in hypercholesterolemic subjects for a minimum 
of 12 weeks was associated with a significant 18.5% reduction 
in LDL-C as compared to placebo.63 In addition, there was a 
significant 3% increase in HDL-C, a significant 8% reduction 
in triglycerides, and a 13% reduction in total cholesterol with 
ezetimibe as compared to placebo. Combination therapy trials 
using ezetimibe plus statin have shown greater efficacy in 
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terms of LDL-C reduction than monotherapy with ezetimibe 
or statin alone.17,65,66 A recent meta-analysis was completed of 
27 double-blind, placebo-controlled, or active comparative 
studies of over 21,000 subjects randomized to ezetimibe 
10 mg daily plus statin or statin alone for a mean treatment 
of 9 weeks.66 Overall, there was a significant 15.1% greater 
observed reduction in LDL-C in the combination therapy with 
ezetimibe as compared monotherapy with statin. Also, there 
was a significant 13.5% greater decrease in non-HDL-C and 
8.6% reduction in high-sensitivity – C-reactive protein. With 
a greater effect on cholesterol values, the study showed that 
a higher percentage of subjects were able to reach ATP III 
treatment targets with the addition of ezetimibe therapy. 
In subjects with established CHD, only 10.3% of subjects 
on statin monotherapy were able to reach an LDL-C goal 
of ,70 mg/dL, while 32.1% of subjects on combination 
therapy with ezetimibe were able to reach this target.
The effectiveness of ezetimibe in lowering cholesterol has 
been tested in various dyslipidemic populations, including 
familial hypercholesterolemia (FH).67 FH is an autosomal 
dominant hereditary disorder caused predominantly by 
mutations in the LDL-receptor gene resulting in less 
functional hepatic LDL receptors and subsequent decreased 
uptake of LDL-C from the blood.68 It has a prevalence of 
1:500 for heterozygotes and 1:1 million for homozygotes 
who have almost complete loss of hepatic LDL-receptor 
activity. FH subjects are often characterized by severely 
elevated LDL-C, dermatologic findings with xanthomas, 
and early onset atherosclerotic vascular disease. While statin 
therapy is the recommended initial treatment of choice along 
with lifestyle intervention, many FH subjects are frequently 
unable to reach LDL-C goals even on high-dose statin.69 The 
additive effect of the addition of ezetimibe to statin therapy 
therefore makes ezetimibe an attractive add-on option for 
undertreated FH subjects.70 In ENHANCE, 720 heterozygous 
FH subjects were randomized to simvastatin 80 mg daily plus 
either ezetimibe 10 mg daily or placebo.17 After 24 months 
of treatment, the simvastatin plus ezetimibe group had 
significantly greater LDL-C reduction as compared to the 
statin-only group (−55.6% vs −39.1%; P , 0.01). Given 
the low prevalence of homozygous FH subjects, there have 
been only a small number of randomized controlled trial 
trials testing ezetimibe in this population. One such trial 
randomized 50 homozygous FH subjects who were already 
receiving a background of 40 mg daily of simvastatin or 
atorvastatin to either increased statin to 80 mg daily, 40 mg 
daily of statin plus ezetimibe 10 mg daily, or to 80 mg 
of statin plus ezetimibe 10 mg daily.67 After 12 weeks of 
therapy, there was a greater decrease in LDL-C with addition 
of ezetimibe to either 40 or 80 mg of statin as compared to 
doubling of statin to 80 mg from 40 mg daily without the 
addition of ezetimibe (21%–27% vs 7%).
Ezetimibe can effectively lower sterol levels in subjects 
with sitosterolemia by inhibiting intestinal plant sterol 
absorption.71–73 An autosomal recessive disorder, sitosterolemia 
is a condition caused by mutations in the ABC transporter 
genes, ABCG5 and ABCG8, which reduce the ability of 
intestinal cells to transfer free cholesterol back to the intestinal 
lumen and from the liver into the bile.36 This reduction 
leads to an increase in serum sterol levels of sitosterol and 
campesterol, and results in the development of early onset 
atherosclerotic vascular disease. Given the inability of statins 
to reduce plant sterol levels and the incomplete lowering of 
sterol levels with other treatments such as low-sterol diets and 
bile-acid binding resins, ezetimibe has emerged as an effective 
alternative strategy.72 In hypercholesterolemic subjects 
without a diagnosis of sitosterolemia, ezetimibe therapy for 
2 weeks was shown to lower sitosterol and campesterol levels 
by 41% and 48%, respectively.74 In one small multicenter 
study, 37 subjects with sitosterolemia were randomized to 
placebo or ezetimibe 10 mg daily. After 8 weeks of therapy, 
sterol levels were reduced by 21% in the ezetimibe group and 
increased by 4% in the placebo group. The reduction in sterols 
with ezetimibe was seen despite subjects concurrently taking 
bile-acid binders or statins.71
Several trials have evaluated the use of ezetimibe in 
patients with diabetes or metabolic syndrome who often have 
an atherogenic lipid profile consisting of elevated LDL-C and 
triglycerides and low HDL-C.75–78 The diagnosis of diabetes is 
considered a CHD-risk equivalent, and current NCEP guidelines 
recommend a similar LDL-C goal for patients with established 
CHD or diabetes.12 Metabolic syndrome is characterized by 
a combination of risk factors, including dyslipidemia with 
elevated triglycerides and low HDL-C, hypertension, obesity 
based upon waist circumference, and insulin resistance with 
impaired fasting glucose.79 Similar to diabetes, the presence 
of metabolic syndrome is associated with a high risk of 
cardiovascular events. In the Vytorin vs Atorvastatin in Patients 
with Type 2 Diabetes Mellitus and Hypercholesterolemia 
(VYTAL) trial, 1229 subjects with diabetes and dyslipidemia 
were randomized to combination therapy with ezetimibe 
10 mg/day plus simvastatin 20 mg/day vs atorvastatin 
10–20 mg/day or to ezetimibe 10 mg/day plus simvastatin 
40 mg/day vs  atorvastatin 40 mg/day.76 After 6 weeks of therapy, 
combination therapy with ezetimibe plus simvastatin had 
greater LDL-C reduction as compared with atorvastatin both 
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at the low dose (−53.6% vs −38.3%, respectively) and the high 
dose (−57.6% vs −50.9%, respectively). In addition to a greater 
ability to lower LDL-C, combination therapy with ezetimibe 
was better in lowering total cholesterol and non-HDL-C and in 
raising HDL-C. As compared to the atorvastatin 10-mg dose, 
ezetimibe 10-mg/simvastatin 20-mg dose was associated with a 
greater reduction in triglyceride levels. In another study testing 
an identical protocol as VYTAL in subjects with metabolic 
syndrome, a similar result was documented with combination 
therapy, with ezetimibe and simvastatin achieving a greater 
reduction in LDL-C and non-HDL-C and greater increase in 
HDL-C as compared to atorvastatin monotherapy.75
Safety
Though side effects have been reported with all  lipid-
altering therapies such as statins, niacin, and fibrates, life-
threatening toxicities are rare and the overall safety profile of 
these therapies is quite favorable.80–82 The safety of ezetimibe 
as monotherapy or in combination with other lipid-modifying 
agents such as statins has been well documented.63,75 In terms 
of elevations in liver function tests, ezetimibe appears to cause 
similar elevations in transaminases (three times the upper limit 
of normal with alanine transaminase or aspartate transaminase) 
as compared to placebo when given as monotherapy.47 Also, 
as combination therapy with statins, ezetimibe does not 
significantly cause an increase in liver enzymes more than is 
observed with statin therapy alone. In a meta-analysis of 18 
randomized controlled trails evaluating statin plus ezetimibe 
or placebo in 14,471 subjects, the incidence of elevations 
in liver enzymes was not statistically different between the 
two groups.66 Life-threatening liver failure with ezetimibe 
as monotherapy or in combination with statins is extremely 
rare, with only a handful of published reported cases.83–85 
Myalgias with or without myositis and elevations in creatinine 
kinase are commonly reported with treatment with statins.86 
The addition of ezetimibe to statin therapy does not appear 
to increase the incidence of elevated creatinine kinase levels 
beyond what is noted with treatment with statin alone. A 
meta-analysis of seven randomized controlled trials showed 
that monotherapy with ezetimibe or in combination with 
statin was not associated with an increased risk of myositis 
as compared to placebo or monotherapy with statin.87
Several epidemiological trials have raised concerns 
of an increased risk of cancer associated with low total 
serum cholesterol levels that have been reproduced in a 
small number of randomized controlled statin trials.5,88–91 
The recent publication of the Simvastatin and Ezetimibe 
in Aortic Stenosis (SEAS) study raised similar concerns 
for cancer with treatment with ezetimibe plus statin.92 
In SEAS, 1873 subjects with a history of asymptomatic 
aortic stenosis were randomized to ezetimibe 10 mg/day 
and simvastatin 40 mg/day or placebo. There was a higher 
rate of cancer incidence in the ezetimibe/simvastatin group 
(11.1%) than in the placebo group (7.5%). However, a 
combined analysis of two larger ezetimibe-plus-statin 
trials that were ongoing at the time of the analysis did not 
support such a hypothesis. In this interim analysis, incident 
cancer cases from the Study of Heart and Renal Protection 
(SHARP) and Improved Reduction of Outcomes: Vytorin 
Efficacy International Trial (IMPROVE-IT) studies with 
20,617 subjects showed no increased risk of cancer with 
treatment with ezetimibe plus statin as compared to statin 
alone.93 Also, the study showed that there was no increased 
risk of new cancer diagnosis associated with duration of 
treatment. Since the publication of this combined analysis, 
the SHARP trial has been completed and confirmed no 
difference in cancer rates between the combination therapy 
and placebo (9.4% vs 9.5%, P = 0.89).65 Final cancer-event 
data is not yet available for the IMPROVE-IT trial, which 
is ongoing, but no recommendations for early termination 
of the trial have been reported by the data-monitoring and 
safety board, which suggests that no significant increase in 
cancer risk has been detected.
Imaging trials evaluating effects  
on atherosclerosis
The vascular effects of ezetimibe on atherosclerosis 
progression have been investigated in several trials using 
ultrasound measurements of CIMT.17,94,95 Numerous 
population studies have documented CIMT as a marker for 
CHD risk. Documenting changes to CIMT has become a 
common surrogate marker of atherosclerosis progression or 
regression in evaluating the clinical effectiveness of lipid-
altering therapies.96 The ENHANCE study investigated 
the vascular effect as measured by CIMT of combination 
therapy with simvastatin 80 mg/day plus either ezetimibe 
10 mg/day or placebo in subjects with heterozygous FH.17 
After 24 months of treatment and despite a significant 
difference in LDL-C lowering (−55.6% vs −39.1%, P , 0.01) 
favoring combination therapy with ezetimibe, there was no 
significant difference in CIMT measurements (+0.0033 mm 
for placebo vs 0.0182 mm for ezetimibe, P = 0.15). This 
negative finding was contrary to the prior Atorvastatin Versus 
Simvastatin on Atherosclerosis Progression (ASAP) trial, 
which showed that high-dose treatment using atorvastatin 
80 mg/day in subjects with heterozygous FH led to a 
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greater reduction in LDL-C as compared to treatment with 
moderate-dose simvastatin of 40 mg/day.97 This difference in 
LDL-C reduction was associated with regression of CIMT 
of −0.031 mm in the atorvastatin group and progression 
of +0.036 mm in the simvastatin group (P = 0.0001 for 
between-group comparison). Though ENHANCE failed to 
produce similar effects on CIMT as seen in ASAP, several 
fundamental differences exist between the two study 
populations that may account for the discordant findings. 
The baseline CIMT seen in ENHANCE (0.70 mm) was 
significantly thinner than in ASAP (0.92 mm). In addition, 
the change in CIMT over 2 years in the monotherapy 
groups treated with simvastatin was significantly less in 
ENHANCE (0.0058 mm) than ASAP (0.0360 mm), despite 
similar effects on LDL-C. These findings in ASAP and 
ENHANCE suggest that the heterozygous FH subjects in 
ENHANCE had been previously well treated with chronic 
statin therapy and may have entered the study with carotid 
arteries already depleted of lipid and therefore resistant to 
further changes in response to new lipid therapies.98 Support 
for this hypothesis was provided by data from the Carotid 
Atorvastatin Study in Hyperlipidemic post-Menopausal 
Women: A Randomized Evaluation (CASHMERE) trial. 
CASHMERE randomized 398 postmenopausal women 
with moderate hypercholesterolemia to treatment with 
atorvastatin 80 mg daily, hormone replacement therapy alone, 
combination, or placebo and measured change in CIMT as a 
vascular outcome.99 After 12 months of therapy, there was no 
reported change in CIMT despite greater LDL-C reduction 
on high-dose atorvastatin as compared to placebo. The mean 
baseline CIMT was 0.69 mm, which was similar to that of 
ENHANCE. This low baseline CIMT measurement observed 
in both trials likely limited the measurable incremental 
change to carotid atherosclerosis in response to additional 
lipid-lowering therapy.
A positive impact on carotid atherosclerosis using 
ezetimibe was observed in the Stop Atherosclerosis in Native 
Diabetics Study (SANDS).94,100 SANDS randomized diabetic 
subjects to aggressive care with target LDL-C ,70 mg/dL 
and systolic blood pressure ,115 mmHg or to standard 
care with target LDL-C , 100 mg/dL and systolic blood 
pressure , 130 mmHg. Ezetimibe was added on to statin 
therapy in subjects not able to meet LDL-C targets. Change 
in carotid IMT was compared between the aggressive versus 
standard treatment groups and between subjects receiving 
statins plus ezetimibe versus statins alone. After 36 months 
of therapy, LDL-C was reduced similarly in the aggressive 
treatment group receiving statins plus ezetimibe (−31 mg/dL) 
or statins alone (−32 mg/dL). Mean baseline CIMT in SANDS 
was 0.81 mm as compared to 0.69 mm seen in ENHANCE. 
In the standard therapy group, there was progression of 
CIMT by +0.039 mm, while the aggressively treated group 
showed CIMT regression from baseline in both the ezetimibe 
(−0.025 mm) and nonezetimibe (−0.012 mm) subjects. In 
multivariate analysis, change in CIMT was related to degree 
of LDL-C reduction independent of specific choice of lipid-
lowering therapy.
Further support for the vascular benefits of combination 
therapy with ezetimibe was reported in the Vytorin on 
Carotid Intima-Media Thickness and Overall Arterial 
Rigidity (VYCTOR) study, which randomized 90 coronary 
artery disease subjects to pravastatin 40 mg/day ± ezetimibe 
10 mg/day, simvastatin 40–80 mg/day, or simvastatin 
20–40 mg/day ± ezetimibe 10 mg/day with a primary 
end point of change in CMIT.101 After 1 year of therapy, 
there was significant reduction in LDL-C to a mean level 
of 45–48 mg/dL in the three groups. Baseline CIMT 
was 1.23–1.33 mm, almost twice that of the baseline in 
ENHANCE. Follow-up measurement of CIMT showed 
a significant reduction in all three groups to a level of 
0.90–0.93 mm. The results of SANDS and VYCTOR are 
contradictory to the outcome observed in ENHANCE and 
suggest that treatment with ezetimibe can regress carotid 
atherosclerosis if there is a sufficiently thick CIMT at 
baseline.
Despite the positive results of the SANDS and VYCTOR 
trials, additional questions were raised regarding the vascular 
benefits of ezetimibe following the early termination of the 
Arterial Biology for the Investigation of the Treatment Effects of 
Reducing Cholesterol 6 – HDL and LDL Treatment Strategies 
(ARBITER 6 – HALTS) study.102,103 ARBITER 6 randomized 
363 coronary artery disease subjects with CHD or CHD 
equivalent, treated LDL-C ,100 mg/dL on background statin 
therapy and low HDL-C to treatment with ezetimibe 10 mg/
day or extended-release niacin target to 2000 mg/day.95 The 
primary end point of the study was change in mean CIMT. 
The study was stopped early after 14 months of follow-up 
after reaching a prespecified efficacy end point. Changes to 
lipid profiles were as expected with treatment, with niacin 
raising HDL-C by 18.4% to 50 mg/dL and ezetimibe lowering 
LDL-C by 19.2% to 66 mg/dL. A significant reduction in CIMT 
(−0.0142 mm, P = 0.001) in the niacin group was reported, 
while a nonsignificant reduction (−0.0007 mm, P = 0.84) was 
noted in the ezetimibe group. The authors concluded based 
upon these results that treatment with niacin in combination 
with statin was superior to ezetimibe on regression of CIMT. 
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These results are consistent with prior data documenting 
niacin’s ability to stabilize or regress atherosclerosis and lend 
support to the use of niacin in the treatment of low HDL-C. 
However, several issues exist in trying to extrapolate these 
findings to conclude on the effectiveness of ezetimibe on carotid 
atherosclerosis. First, ARBITER-6 was designed to evaluate 
the treatment of subjects with low HDL-C and controlled 
LDL-C. Such a population was ideally suited for therapy with 
niacin and not with ezetimibe which is used primarily to reduce 
LDL-C. While niacin treatment raised HDL-C by 7.5 mg/
dL, therapy with ezetimibe lowered HDL-C by 2.8 mg/dL. 
Additionally, as noted in prior carotid imaging trials including 
ASAP and ENHANCE, changes in carotid atherosclerosis 
occur in the first 1–2 years after initiating LDL-C-lowering 
therapy and are not expected in subjects who have been on 
chronic lipid-lowering treatment. ARBITER 6 subjects were 
on a background of aggressive statin therapy for an average of 
6 years prior to study enrollment, which could have impacted 
their capacity for additional LDL-C reduction with ezetimibe 
to reduce CIMT. Also, the trial was stopped prematurely, with 
over 40% of the subjects not having undergone follow-up 
CIMT measurements, and this could have minimized any 
possible vascular effects due to ezetimibe. Based on these 
methodological study design flaws, definitive conclusions on 
the presence or absence of vascular benefit of ezetimibe cannot 
be made using data presented in ARBITER-6.
Clinical outcome trials
The clinical efficacy of ezetimibe treatment was evaluated in 
the SEAS study, where 1873 subjects with mild to moderate 
aortic stenosis without indication for lipid-lowering therapy 
were randomized to ezetimibe 10 mg/day plus simvastatin 
40 mg/day or placebo.92 The primary end point was a composite 
of need for aortic valve surgery and cardiovascular events. 
After 4 years of therapy, combination therapy with ezetimibe 
reduced LDL-C by 61% as compared to placebo. While there 
was no significant difference in the primary end point, major 
cardiovascular events with fatal and nonfatal myocardial 
infarction were significantly reduced by 41% in the simvastatin 
plus ezetimibe group (Figure 3). This cardiovascular event 
reduction was proportional to the magnitude of LDL-C 
change and was only apparent in subjects with less severe 
aortic stenosis, defined as tertiles 1 and 2 as based upon aortic 
jet velocity.104 This degree of event reduction based upon the 
level of LDL-C reduction was similar to what was previously 
observed in a meta-analysis of 14 statin trials showing the 
benefit of statin therapy versus placebo completed by the 
Cholesterol Treatment Trialists’ Collaboration.80
Similar evidence supportive of a cardiovascular benefit in 
using statin plus ezetimibe treatment was noted in the SHARP 
trial.65 In SHARP, subjects with chronic kidney disease with and 
without dialysis dependence were randomized to simvastatin 
20 mg/day plus ezetimibe 10 mg/day or placebo. After 5 years 
of therapy, there was a significant 17% reduction in major 
atherosclerotic events in the ezetimibe groups as compared to 
placebo (P = 0.0021). Risk reduction was again found to be 
proportional to magnitude of LDL-C reduction. No increased 
risk of adverse events was reported, including myopathy and 
rhabdomyolysis. This positive outcome was in contrast to two 
previously reported negative trials evaluating lipid-lowering 
with statins in renal disease subjects; A Study to Evaluate the 
Use of Rosuvastatin in Subjects on Regular Hemodialysis: An 
Assessment of Survival and Cardiovascular Events (AURORA) 
and German Diabetes and Dialysis Study (4D).105,106 In addition 
to the fact that SHARP was a significantly larger trial with three 
times greater enrollment than AURORA and 4D combined, 
the likely main explanation for the discrepant findings was 
that the SHARP population had less advanced kidney disease. 
While AURORA and 4D evaluated lipid therapy in subjects 
who were already undergoing hemodialysis, the SHARP trial 
only had a third of its population being dialysis-dependent. 
Lipid therapy would be expected to benefit less advanced 
kidney disease subjects, who predominantly succumb to 
deaths related to atherosclerotic-based heart disease, but not in 
dialysis-dependent subjects, who experience more arrhythmia-
related deaths.107
Despite the atherosclerosis regression documented in 
SANDS and VYCTOR and cardiovascular benefit seen 
in SEAS and SHARP using combination therapy with 
ezetimibe, the negative outcomes reported from ENHANCE 
and ARBITER 6 produced signif icant controversy 
on the clinical value of ezetimibe in the treatment of 
hypercholesterolemia.23,98,102 Also, to date, no randomized 
trial has shown a significant reduction in clinical events 
with combination therapy using ezetimibe plus statin versus 
statin alone. Therefore, the results from the soon-to-be-
completed IMPROVE-IT are highly anticipated.108 The goal 
of IMPROVE-IT is to evaluate the effect of additional LDL-C 
lowering using ezetimibe on top of intensive background 
statin therapy on cardiovascular events in 18,000 subjects 
who have had recent acute coronary syndromes. But while 
the trial is not expected to be completed until June 2013, 
questions already exist about the ability of the trial to detect 
incremental benefit of ezetimibe added on to statin therapy. 
Subjects in IMPROVE-IT were treated at baseline with 
optimal medical therapy post–acute coronary syndrome and 
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were thought to be able to reach aggressive LDL-C targets 
based upon NCEP ATP III updated recommendations with 
treatment with simvastatin 40 mg/day plus placebo (the trial 
will be comparing mean attained LDL-C levels of 66 mg/dL 
and 52 mg/dL).109 Given the already low LDL-C levels and 
reduced cardiovascular events with simvastatin-only therapy 
in this population, the further reduction of cardiovascular 
events with the addition of ezetimibe will likely be of modest 
value. Beyond the large sample size, IMPROVE-IT will need 
an adequate number of events to provide enough power to 
detect the expected small difference between the ezetimibe 
and placebo groups. Ideally, a trial comparing ezetimibe 
monotherapy versus placebo in hypercholesterolemic subjects 
would provide the best answer on ezetimibe’s ability to lower 
LDL-C and subsequently affect cardiovascular events. But 
unfortunately, given the long-established benefit of statin 
therapy, a cholesterol trial without statin therapy would not 
be possible today, particularly in subjects with CHD.
Conclusion
In the current treatment of cardiovascular disease, many subjects 
fail to reach LDL-C targets or remain at high risk for CHD 
events despite optimal statin and medical therapy. Ezetimibe 
inhibits intestinal cholesterol absorption and is effective 
in lowering cholesterol as monotherapy or in combination 
with statins in several populations, including those with FH, 
sitosterolemia, and insulin resistance. Significant controversy 
has been generated regarding the clinical effectiveness of 
ezetimibe, particularly after the publication of ENHANCE 
and ARBITER-6 despite both trials having significant 
methodological flaws that limited their ability to evaluate the 
benefit of ezetimibe. Growing data suggest that ezetimibe in 
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Figure 3 Proportional reduction in major ischemic events by mean decrease in LDL-C (mmol/L) in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial (tertiles 1, 
2, and 3 for severity of aortic valve stenosis) compared to 14 randomized trials in the Cholesterol Treatment Trialists meta-analysis. 
Copyright © 2010, Elsevier. Adapted with permission from Holme I, Boman K, Brudi P, et al. Observed and predicted reduction of ischemic cardiovascular events in the 
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et al.65 1 mmol/L approximates to 39 mg/dL of LDL-C.
Abbreviation: LDL-C, low-density lipoprotein cholesterol.
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combination with statin has a positive effect on the progression 
of atherosclerosis and reduces cardiovascular events in subjects 
at risk for CHD, including those with chronic kidney disease. 
Results from IMPROVE-IT are forthcoming and may help 
to guide better the use of ezetimibe in very high-risk CHD 
populations. Until that time and based upon the current available 
data, ezetimibe should remain a viable adjunct to statin therapy 
in the treatment of hypercholesterolemia.
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